Latest News and Press Releases

WALTHAM, Mass., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU) today announced it has filed a Form 15 with the Securities and Exchange Commission completing the process of...

WALTHAM, Mass., Aug. 04, 2017 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU) today announced it has filed a Form 25 with the Securities and Exchange Commission in furtherance of its...

WALTHAM, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU) today announced the adoption of a plan to wind-up and liquidate the Company subject to shareholder approval...

WALTHAM, Mass., July 03, 2017 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that it will pursue strategic alternatives for the Company and will reduce the Company’s...

WALTHAM, Mass., May 12, 2017 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial results for its first quarter of 2017, ended March 31, 2017, and provided a...

WALTHAM, Mass., April 18, 2017 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on the genetics of chronic inflammation, today announced financial and...

WALTHAM, Mass., March 20, 2017 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today the presentation...

WALTHAM, Mass., March 13, 2017 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has...

WALTHAM, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has...

WALTHAM, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has...